Unknown

Dataset Information

0

Optimising use of thiopurines in inflammatory bowel disease.


ABSTRACT: Azathioprine (AZA) and 6-mercaptopurine (6-MP) are the most widely used immunosuppressive therapies in inflammatory bowel disease. Pretreatment measurement of thiopurine methyltransferase (TPMT) activity is recommended and although conventional practice is to use a dose of 2 mg/kg AZA (1 mg/kg 6-MP), higher doses of 2.5 mg/kg AZA or more may be required in some patients, particularly if TPMT activity is high. Dose raising is limited by toxicity, and a robust monitoring system is mandatory. Patients with side effects to AZA may tolerate 6-MP but pancreatitis is a contraindication to switching. Metabolite monitoring is not widely available but may be useful, particularly if non-compliance is possible or where metabolite shunting to 6-methylmercaptopurine is suspected, on the basis of non-response or toxicity. It may allow dose optimisation before switching to alternative immunosuppressants. The drug appears safe in pregnancy and breast feeding. Long term duration of therapy is a balance between benefits in relation to the underlying disease extent, activity and aggressiveness, and the risk of neoplasia, particularly lymphoma.

SUBMITTER: Raj LS 

PROVIDER: S-EPMC5517153 | biostudies-other | 2010 Apr

REPOSITORIES: biostudies-other

Similar Datasets

| PRJNA943357 | ENA
2012-09-12 | E-MTAB-184 | biostudies-arrayexpress
2004-04-20 | GSE1152 | GEO
| S-EPMC9802313 | biostudies-literature
| S-EPMC4126607 | biostudies-literature
2023-07-03 | MSV000092337 | MassIVE
| S-EPMC5965708 | biostudies-literature
2004-04-20 | GSE1142 | GEO
2004-04-20 | GSE1141 | GEO
| S-EPMC4620040 | biostudies-literature